Dopamine receptor D1 and Dopamine receptor D2 (D1 receptor (DRD1), D2 receptor (DRD2))

Dopamine receptor D1 and D2 are two major classes of dopamine receptors found primarily in the central nervous system. Both are G protein-coupled receptors (GPCRs), but they differ in their G protein interactions and physiological effects. D1 receptors couple to Gs proteins, activating adenylyl cyclase and increasing intracellular cAMP, whereas D2 receptors couple to Gi proteins, inhibiting adenylyl cyclase and reducing cAMP production[2][5][6]. These receptors mediate the diverse effects of dopamine on motor control, cognition, motivation, and endocrine functions. Abnormalities in D1 and D2 receptor function are implicated in several diseases, notably Parkinson’s disease, schizophrenia, and substance abuse disorders[2][5][4]. Their importance as drug targets is demonstrated by the wide range of therapeutics—including antipsychotics and anti-parkinsonian agents—that act primarily via modulation of these receptors[1][3][5]. Structurally, both receptors share the seven-transmembrane domain architecture typical of GPCRs[1][3]. Ligands for these receptors include both natural catecholamines and a wide array of synthetic compounds with distinctive receptor subtype selectivity; for example, bromocriptine selectively targets D2 over D1 receptor due to structural differences in the ligand-binding pockets[1][3]. D1 and D2 receptors also form heteromers and interact with other GPCRs, amplifying their functional diversity[4].

Other names

D1RD2Rdopamine D1 receptordopamine D2 receptor

Agonist (stimulates receptor); Antagonist (blocks receptor); Partial agonist (modulates receptor activity)